|
Inmed Pharmaceuticals Inc. (INM) DCF -Bewertung |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
InMed Pharmaceuticals Inc. (INM) Bundle
Verbessern Sie Ihre Anlagestrategien mit dem DCF -Taschenrechner von Inmed Pharmaceuticals Inc. (INM)! Erforschen Sie authentische Finanzdaten, passen Sie Wachstumsprojektionen und -kosten an und beachten Sie sofort, wie sich diese Anpassungen auf den inneren Wert von Inmed Pharmaceuticals Inc. (INM) auswirken.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .8 | 3.0 | 3.3 | 4.2 | 5.4 | 6.9 | 8.8 | 11.3 |
| Revenue Growth, % | 0 | 0 | 0 | 279.61 | 11.18 | 27.79 | 27.79 | 27.79 | 27.79 | 27.79 |
| EBITDA | -6.2 | -7.1 | -12.4 | -7.8 | -5.1 | -.8 | -1.1 | -1.4 | -1.8 | -2.3 |
| EBITDA, % | 100 | 100 | -1584.07 | -261.92 | -153.64 | -20 | -20 | -20 | -20 | -20 |
| Depreciation | .1 | .1 | .4 | .4 | .4 | 2.3 | 3.0 | 3.8 | 4.9 | 6.2 |
| Depreciation, % | 100 | 100 | 46.98 | 14.41 | 13.15 | 54.91 | 54.91 | 54.91 | 54.91 | 54.91 |
| EBIT | -6.3 | -7.2 | -12.8 | -8.2 | -5.5 | -.8 | -1.1 | -1.4 | -1.8 | -2.3 |
| EBIT, % | 100 | 100 | -1631.05 | -276.33 | -166.79 | -20 | -20 | -20 | -20 | -20 |
| Total Cash | 4.2 | 5.3 | 4.5 | 6.4 | 4.8 | 4.2 | 5.4 | 6.9 | 8.8 | 11.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .1 | .2 | .3 | 1.9 | 2.4 | 3.1 | 3.9 | 5.0 |
| Account Receivables, % | 100 | 100 | 8.08 | 6.3 | 7.67 | 44.41 | 44.41 | 44.41 | 44.41 | 44.41 |
| Inventories | .0 | -689.2 | 1.8 | 1.2 | .9 | 3.1 | 4.0 | 5.1 | 6.5 | 8.3 |
| Inventories, % | 100 | 100 | 228.64 | 39.08 | 27.06 | 73.23 | 73.23 | 73.23 | 73.23 | 73.23 |
| Accounts Payable | .7 | .6 | .8 | .4 | .5 | 2.8 | 3.5 | 4.5 | 5.8 | 7.4 |
| Accounts Payable, % | 100 | 100 | 107.03 | 13.16 | 13.62 | 65.36 | 65.36 | 65.36 | 65.36 | 65.36 |
| Capital Expenditure | .0 | .0 | .0 | -.1 | .0 | -.1 | -.1 | -.1 | -.1 | -.2 |
| Capital Expenditure, % | 100 | 100 | -3.59 | -3.91 | -0.20212 | -1.54 | -1.54 | -1.54 | -1.54 | -1.54 |
| Tax Rate, % | -0.09258716 | -0.09258716 | -0.09258716 | -0.09258716 | -0.09258716 | -0.09258716 | -0.09258716 | -0.09258716 | -0.09258716 | -0.09258716 |
| EBITAT | -6.5 | -7.2 | -12.8 | -8.3 | -5.5 | -.8 | -1.1 | -1.4 | -1.8 | -2.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -5.7 | 682.0 | -703.2 | -7.9 | -4.8 | -.1 | 1.2 | 1.5 | 1.9 | 2.5 |
| WACC, % | 6.66 | 6.66 | 6.66 | 6.66 | 6.66 | 6.66 | 6.66 | 6.66 | 6.66 | 6.66 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 5.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 3 | |||||||||
| Terminal Value | 54 | |||||||||
| Present Terminal Value | 39 | |||||||||
| Enterprise Value | 45 | |||||||||
| Net Debt | -4 | |||||||||
| Equity Value | 49 | |||||||||
| Diluted Shares Outstanding, MM | 8 | |||||||||
| Equity Value Per Share | 6.43 |
What You Will Get
- Editable Forecast Inputs: Easily modify key assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: InMed Pharmaceuticals Inc.’s (INM) financial data pre-filled to enhance your analysis.
- Automatic DCF Outputs: The template automatically calculates Net Present Value (NPV) and intrinsic value for your convenience.
- Customizable and Professional: A sleek Excel model that can be tailored to your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, verifying strategies, and streamlining your process.
Key Features
- Real-Life INM Data: Pre-filled with InMed Pharmaceuticals’ historical financials and forward-looking projections.
- Fully Customizable Inputs: Adjust revenue growth, margins, WACC, tax rates, and capital expenditures to fit your analysis.
- Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your customized inputs.
- Scenario Testing: Create multiple forecast scenarios to examine various valuation outcomes.
- User-Friendly Design: Intuitive, organized, and suitable for both professionals and newcomers.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review InMed Pharmaceuticals Inc.'s (INM) pre-filled financial data and forecasts.
- Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you adjust your assumptions.
- Step 5: Analyze the outputs and utilize the results for your investment decisions.
Why Choose This Calculator for InMed Pharmaceuticals Inc. (INM)?
- User-Friendly Interface: Tailored for both newcomers and seasoned professionals.
- Customizable Inputs: Adjust parameters to suit your specific analysis needs.
- Real-Time Adjustments: Instantly view changes to InMed's valuation as you modify inputs.
- Preloaded Data: Comes equipped with InMed's latest financial information for swift evaluations.
- Relied Upon by Experts: A go-to tool for investors and analysts aiming for well-informed decisions.
Who Should Use This Product?
- Pharmaceutical Students: Explore drug development processes and apply your knowledge using real-world data.
- Researchers: Integrate advanced models into your studies or clinical research.
- Investors: Validate your investment strategies and assess valuation scenarios for InMed Pharmaceuticals Inc. (INM).
- Market Analysts: Enhance your analysis with a customizable financial model tailored for biotech companies.
- Healthcare Entrepreneurs: Understand how public biotech firms like InMed Pharmaceuticals Inc. (INM) are evaluated in the market.
What the Template Contains
- Historical Data: Includes InMed Pharmaceuticals Inc.'s (INM) past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate InMed Pharmaceuticals Inc.'s (INM) intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of InMed Pharmaceuticals Inc.'s (INM) financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.